Liviniti LivLite Program expands employer coverage options for high-cost weight-loss drugs
- Bridges the gap for employers contemplating all-or-nothing coverage
- Limits the plan's financial exposure to expensive GLP-1s
- Delivers predictable costs for plans and members
NATCHITOCHES, La., Feb. 26, 2025 -- In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, has introduced a breakthrough solution to help manage the expense that comes with increased access to these high-cost but effective treatments. The fully transparent PBM has launched Liviniti LivLite, a first-of-its-kind weight loss coverage program that gives employers a breakthrough option to respond to employee enthusiasm for GLP-1 medications while offering cost predictability for the health plan.
Liviniti LivLite Program expands employer coverage options for high-cost weight-loss drugs.
With ever-increasing demand for Wegovy®, Zepbound® and other GLP-1s, these medications present significant cost challenges to employers who struggle to balance the financial impact on their health plan with employee desire for coverage. Studies indicate that more than 40% of employees would change jobs to gain GLP-1 coverage and 90% of people with obesity believe insurance should cover obesity treatment.
"Until now, employers had very limited coverage options for weight-loss medications," says LeAnn Boyd, CEO. "Either they cover GLP-1 medications at significant increased cost to the benefit plan or do not cover the medications at all. Knowing that coverage for weight loss treatments is not an easy decision for employers, our Liviniti team innovated a solution that provides affordability, flexibility and access to these medications."
Compatible with preferred provider organization (PPO) and high-deductible (HDHP) medical plans, the Liviniti LivLite weight-loss coverage solution is available to Liviniti clients as well as any other employer. By offering a flexible, stand-alone option, Liviniti helps employers navigate the growing demand for GLP-1 medications without overhauling their current benefit plans. This approach ensures that employees have access to weight-loss treatments while providing companies with a cost-controlled way to support workforce health and employee retention.
By breaking down financial barriers to coverage, Liviniti is empowering employers with a sustainable option to support their employees in achieving their weight loss goals and driving better overall health of their workforce. The American Medical Association notes that obesity is associated with more than 200 comorbidities ranging from several forms of cancer to heart disease and more. Interest in weight-loss drugs continues to grow, with analytics company IQVIA reporting that 124 obesity drugs are currently in development, a third of which are in the GIP/GLP glucagon receptor agonist category.
The Liviniti LivLite solution positions employers ahead of the curve as new anti-obesity treatments emerge and employees anticipate coverage. With today's announcement, Liviniti is leading the way to the future of affordable and accessible obesity care. Find more details about the program at LivLite.
About Liviniti
Liviniti is a pioneer in pharmacy benefit innovation. Built by pharmacists, the company offers pass-through pricing within a fully transparent business model that delivers meaningful savings to clients and optimal health outcomes to members. Founded in 2011 as Southern Scripts and rebranded to Liviniti, the new name reinforces the power of medication to change lives through infinite possibilities. With an approach that delivers savings, clinical value, exceptional service and management of high-cost medications, Liviniti provides pharmacy benefit services to regional and national employers across the U.S. For more information, visit liviniti.com.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
